Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

infections other than COVID-19 meta-analysis

INSIGHT FLU-IVIG (Davey), 2019
 
NCT02287467
RCTconvalescent plasma treatmentplaceboinfections other than COVID-19some concern
-/- inconclusive
    IRC005 Study Team, 2019
     
    NCT02572817
    RCTconvalescent plasma treatmentplaceboinfections other than COVID-19low
    92/48 inconclusive
      IRC002 Study Team, 2017
       
      NCT01052480
      RCTconvalescent plasma treatmentcontrolinfections other than COVID-19some concern
      42/45 inconclusive
        Hung, 2013
         
        NCT01617317
        RCTconvalescent plasma treatmentplaceboinfections other than COVID-19some concern
        17/18 inconclusive

          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).